Batoclimab is under clinical development by Immunovant and currently in Phase II for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According to GlobalData, Phase II drugs for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Batoclimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Batoclimab overview

Batoclimab is under development for the treatment of idiopathic thrombocytopenic purpura (ITP), membranous nephropathy, pemphigus vulgaris, lupus nephritis (LN), myasthenia gravis (MG), Graves' ophthalmopathy, chronic inflammatory demyelinating polyneuropathy (CIDP), Graves disease (GD) and neuromyelitis optica (NMO). It is a fully human monoclonal antibody IgG1 targeting the Fc neonatal receptor (FcRn). It is administered subcutaneously and developed based on OmniAb technology. 

It was under development for warm autoimmune hemolytic anemia.

Immunovant overview

Immunovant is a biopharmaceutical company that focus on developing antibodies for the treatment of autoimmune diseases. The company’s pipeline products include IMVT-1401, a fully human monoclonal antibody that targets the neonatal Fc receptor (FcRn), in Phase II clinical trials for the treatment of myasthenia gravis and thyroid eye disease. It is also evaluating its IMVT-1401 in IND Phase for the treatment of warm autoimmune hemolytic anemia. The company seeks to collaborate with HanAll Biopharma Co Ltd for research and development of next generation FcRn inhibitors. The company has subsidiaries located in Switzerland, Bermuda and the US. Immunovant is headquartered in New York City, New York, the US.

For a complete picture of Batoclimab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.